This article was originally published in The Gray Sheet
Firm is developing automated FISH (fluorescence in situ hybridization) gene-probe technology instrument in conjunction with Mercer Scientific International, Downers Grove, Illinois-based Vysis reports Oct. 29. Slated for release in the first quarter of 1999, the system will consist of a re-engineered version of an existing Carl Zeiss automated slide stainer. Under two separate deals, Mercer assumes manufacturing responsibilities while Carl Zeiss agrees to distribute the system and provide customer maintenance and service
You may also be interested in...
US FDA declines to review the CCR5 antagonist for use in highly treatment-experienced HIV patients. Safety data from an ongoing study should be sufficient to address the agency’s concerns about the higher 700mg dose, CytoDyn management says, but FDA also has questions about the production of the self-injectable syringes.
Mallinckrodt's drug to treat hepatorenal syndrome met its primary endpoint of HRS reversal but FDA wants reassurance that this surrogate endpoint translates into a treatment effect on clinical outcomes. A greater incidence of respiratory failure in those receiving terlipressin "remains a significant safety concern," the agency says.
Lead immuno-oncology asset NC318 targeting Siglec-15 showed encouraging early activity in patients refractory to PD-1/L1 inhibitors, but now Phase II plans are scuttled in lung and ovarian cancers.